SIG
FPRX

Stanford Investment Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Stanford Investment Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-57
Closed -$1K – 372
2015
Q1 		$1K Buy
+57
New +$1.44K ﹤0.01% 343

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stanford Investment Group's FPRX Position: Q2 2015 in Review

Stanford Investment Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2015, closing a stake of 57 shares — an estimated $1K sold.

Stanford Investment Group first reported a position in FPRX in Q1 2015 and held it in 1 quarter. The position peaked at $1K in Q1 2015. 107 funds tracked by Wall St. Rank hold FPRX as of Q2 2015.

  • Stanford Investment Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Stanford Investment Group sold 57 Five Prime Therapeutics, Inc. shares in Q2 2015, an estimated $1K.
  • Stanford Investment Group first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Stanford Investment Group's Five Prime Therapeutics, Inc. position peaked at $1K in Q1 2015.
  • 107 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2015.

Based on Stanford Investment Group's 13F filing for Q2 2015, filed 18 Nov 2016.